Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Synopsis

Characteristics of Patients Co-infected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus, Buenos Aires, Argentina, March–June 2020

Lucila M. Carosella, Daniel Pryluka, Aldo Maranzana, Laura Barcan, Rosana Cuini, Cristina Freuler, Alfredo Martinez, Tomás Rivero Equiza, Carolina Rodriguez Peria, Diego Yahni, Martin E. StryjewskiComments to Author , and for the COVIDENGUE Study Group1
Author affiliations: Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina (L.M. Carosella, A. Martinez, T. Rivero Equiza, M.E. Stryjewski); Sanatorio Otamendi, Buenos Aires (D. Pryluka); General Hospital de Agudos Parmenio Piñero Gobierno de la Ciudad, Buenos Aires (A. Maranzana); Hospital Italiano de Buenos Aires, Buenos Aires (L. Barcan); Hospital de Agudos Dr. Teodoro Álvarez, Buenos Aires (R. Cuini); Hospital Alemán, Buenos Aires (C. Freuler); Sanatorio de Los Arcos, Buenos Aires (C. Rodriguez Peria),; Sanatorio Mutual del Transporte Automotor, Buenos Aires (D. Yahni)

Main Article

Table

Clinical characteristics and laboratory parameters at hospitalization for 13 patients co-infected with SARS-CoV-2 and dengue virus, Buenos Aires, Argentina, March–June 2020*

Characteristics
 Value
Age, y
 37 (29–50)
Sex
F 6 (46)
M
 7 (54)
Concurrent condition†
 7 (54)
Signs or symptoms
Fever at hospitalization 13 (100)
Median temperature at hospitalization, °C 38.0 (38.0–38.8)
Median duration of fever, d 7 (4–9)
Cough 3 (23)
Headache 8 (61)
Myalgia 7 (54)
Rash 3 (23)
Chills 3 (23)
Dyspnea 2 (15)
Diarrhea 2 (15)
Odinophagia 2 (15)
Nasal congestion 2 (15)
Anosmia 1 (8)
Dysgeusia 1 (8)
Arthralgia 1 (8)
Nausea or vomiting 1 (8)
Pneumonia 5 (38)
Bilateral
 2 (15)
Laboratory findings
Median hematocrit, % 44 (36–46)
Median hemoglobin, g/dL 14.1 (13.0–15.0)
Median leukocytes × 103 cells/μL 4.3 (2.26–7.9)
Leukopenia, <4 × 103 cells/μL 4 (31)
Median lymphocyte count × 103 cells/μL 0.81 (4.1–1.16)
Lymphopenia, <1.5 × 103 cells/μL 12 (92)
Platelets ×103/μL 172 (116–196)
<150 ×103/μL 6 (46)
<100 ×103/μL 3 (23)
Abnormal AST level 6 (46)
Abnormal ALT level
 6 (46)
Diagnosis of dengue
NS1 detection 8 (61)
Real-time PCR 4 (31)
Serologic conversion
 1 (8)
Clinical outcomes
Need for supplemental oxygen 1 (8)
ICU 0
Median length of stay in hospital, d 12 (10–14)
Severe dengue 0
Hospital discharge 13 (100)
Full recovery at follow-up at 4 wk 13 (100)
Rehospitalization at 4 wk 0
Death
 0
Therapy for infection with SARS-CoV-2
Lopinavir/ritonavir 3 (23)
Hydroxychloroquine 1 (8)
Antimicrobial drug therapy 6 (46)

*Values are no. (%) or median IQR. ALT, alanine aminotransferase; AST, aspartate aminotransferase, ICU, intensive care unit; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†Includes obesity 3; chronic obstructive pulmonary disease 2; hypertension 2; smoking 2; diabetes 1; and cirrhosis 1.

Main Article

1Members of the COVIDENGUE Study Group are listed at the end of this article.

Page created: December 02, 2020
Page updated: January 23, 2021
Page reviewed: January 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external